ten23 health has obtained Swissmedic GMP authorisations for the manufacturing and testing of Advanced Therapy Medicinal Products at its Basel and Visp facilit
The new generation of life sciences jobs does not fit traditional labels. Digital Life Sciences reflects the growing need for hybrid profiles able to connect biotechnology, manufacturing, automation, AI and data-driven processes.
The new generation of life sciences jobs does not fit traditional labels Read More »
As injectable medicines become more complex, the need for integrated development, manufacturing and quality capabilities continues to grow. With expanded sterile production lines in Visp, FDA-approved QC laboratories and 240 employees across Switzerland, ten23 health illustrates how specialised CDMO expertise is strengthening Valais’ role in biopharma manufacturing and injectable drug development.
ten23 health and biopharma execution capacity in Valais Read More »
Located at the BioArk Tech Park in Visp, MINTworld offers pupils, teachers and visitors the opportunity to discover science, technology, engineering and mathematics through hands-on activities and interactive workshops. Created by BioArk, the Canton of Valais and Lonza, the centre helps promote STEM education across Valais. This autumn, the first 1,000 pupils registered for a workshop can benefit from free travel to and from Visp thanks to complimentary SBB group tickets.
MINTworld: Where curiosity becomes the engine of innovation Read More »
Established in Visp in 1897, Lonza has developed one of the world’s largest integrated biomanufacturing sites. Today, the Valais site combines large-scale biologics production, advanced modalities and chemical manufacturing within a global CDMO network serving pharmaceutical and biotech companies worldwide. The Visp site is Lonza’s largest production hub globally and a central pillar of its
Lonza Visp: Large-Scale Biomanufacturing and Advanced Modalities Read More »
The Switzerland–UK Call for Projects offers Swiss startups and SMEs a powerful opportunity to collaborate with UK partners, secure innovation funding and accelerate the development of market-ready solutions.
Switzerland /UK Innovation Call: A Fast Track to New Markets and Strategic Partnerships Read More »
Novochizol has published new preclinical results in Pharmaceutics on an intranasal vaccine approach against highly pathogenic avian influenza A/H5, formulated with its chitosan-derived delivery platform.
On June 16, BioArk Tech Park in Monthey had the pleasure of welcoming around 120 representatives from the Canton of Valais for a discovery afternoon dedicated to innovation, education, and life sciences.
Discovering BioArk Ecosystem: OSP and SHE Visit Monthey Tech Park Read More »
Ninsun Biotech will present NinStem Lung™, its diagnostic test in development for predicting response to immunotherapy in non-small cell lung cancer, at the IFODS ONCO STARTUP SUMMIT in Paris on 18 June 2026.
Ninsun Biotech to present an NSCLC immunotherapy response biomarker at IFODS Read More »
Bioscibex, a startup hosted at BioArk TechPark in Monthey, has been awarded the 2026 Prix Créateurs BCVS. The recognition highlights SW1NGO, an innovative bioreactor that simplifies cell therapy production, reduces costs and contamination risks, and supports the development of treatments for cancer and autoimmune diseases.
BioArk startup Bioscibex wins Prix Créateurs BCVS 2026 Read More »
